Literature DB >> 6751435

The clinical significance of the morphological subdivision of diffuse "histiocytic" lymphoma: a study of 162 patients treated by the Southwest Oncology Group.

B N Nathwani, D O Dixon, S E Jones, R J Hartsock, J W Rebuck, G E Byrne, W W Sheehan, H Kim, C A Coltman, H Rappaport.   

Abstract

We grouped 162 patients wtih advanced, diffuse histiocytic lymphoma (DHL) into various morphological subtypes to ascertain whether there were any significant differences in survival among them. These patients were staged and treated from 1972 to 1977 according to the protocols of the Southwest Oncology Group. Of the 159 patients on whom a consensus on the diagnosis was reached, 115 were classified morphologically as having large non-cleaved, 26 as B-immunoblastic, 9 as large cleaved, and 6 as T-immunoblastic. The 3 remaining patients did not fit any of these subtypes, but each had a single prominent nucleolus in most tumor cells ("prominent nucleolus" type). Morphological subdivision of DHL did not identify any subgroup of patients with a significantly longer survival, but clinical parameters such as stage, symptoms, and type of treatment significantly influenced survival times.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6751435

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  5 in total

1.  Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials.

Authors:  Heinz-Wolfram Bernd; Marita Ziepert; Christoph Thorns; Wolfram Klapper; Hans-Heinrich Wacker; Michael Hummel; Harald Stein; Martin-Leo Hansmann; German Ott; Andreas Rosenwald; Hans-Konrad Müller-Hermelink; Thomas F E Barth; Peter Möller; Sergio B Cogliatti; Michael Pfreundschuh; Norbert Schmitz; Lorenz Trümper; Silvia Höller; Markus Löffler; Alfred C Feller
Journal:  Haematologica       Date:  2009-11       Impact factor: 9.941

2.  Molecular analysis of a chromosomal translocation, t(9;14)(p13;q32), in a diffuse large-cell lymphoma cell line expressing the Ki-1 antigen.

Authors:  H Ohno; T Furukawa; S Fukuhara; S Q Zong; H Kamesaki; T B Shows; M M Le Beau; T W McKeithan; T Kawakami; T Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

Review 3.  Management of localized non-Hodgkin's lymphoma.

Authors:  R G MacKenzie; J J Rusthoven
Journal:  CMAJ       Date:  1985-09-15       Impact factor: 8.262

4.  Beyond "bad news": the diagnosis, prognosis and classification of lymphomas and lymphoma patients in the age of biomedicine (1945-1995).

Authors:  Peter Keating; Alberto Cambrosio
Journal:  Med Hist       Date:  2003-07       Impact factor: 1.419

5.  Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma.

Authors:  R A Cowan; M Jones; M Harris; W P Steward; J A Radford; J Wagstaff; D P Deakin; D Crowther
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.